Literature DB >> 21922234

[Volume regulation in cardiac insufficiency : possibilities of telephone coaching and peritoneal dialysis].

M W Bergmann1, K-H Kuck, I Krenz.   

Abstract

Volume retention is the hallmark of progressive heart failure, both systolic and diastolic (heart failure with preserved ejection fraction). It represents the cause of the main symptoms (dyspnea, edema, liver synthesis) and also the main target of drug therapy. Antagonizing excessive volume retention is also the most important therapy element. Many patients can be stabilized with sequential nephron blockade (thiazide + loop diuretics) combined with afterload reduction [blockade of the RAAS (renin-angiotensin-aldosterone) system]. Personal patient coaching combined with telemetric components (weight, blood pressure) has evolved as another cornerstone of treatment in heart failure patients. If these measures are insufficient to control volume retention, renal replacement therapy is effective and can improve quality of life. More specifically, aquaresis via peritoneal dialysis has been shown to be effective and adequate to control volume overload. Many patients may qualify for this evolving therapy as it effectively prevents repeat hospitalization for heart failure decompensation, can be performed in an out-patient setting and has a low complication rate, thus significantly improving quality of life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21922234     DOI: 10.1007/s00059-011-3505-9

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  6 in total

Review 1.  Place of peritoneal dialysis in the management of treatment-resistant congestive heart failure.

Authors:  R Mehrotra; P Kathuria
Journal:  Kidney Int Suppl       Date:  2006-11       Impact factor: 10.545

2.  Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study.

Authors:  Friedrich Koehler; Sebastian Winkler; Michael Schieber; Udo Sechtem; Karl Stangl; Michael Böhm; Herbert Boll; Gert Baumann; Marcus Honold; Kerstin Koehler; Goetz Gelbrich; Bridget-Anne Kirwan; Stefan D Anker
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

3.  Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data.

Authors:  Gerasimos S Filippatos; Mustafa I Ahmed; James D Gladden; Marjan Mujib; Inmaculada B Aban; Thomas E Love; Paul W Sanders; Bertram Pitt; Stefan D Anker; Ali Ahmed
Journal:  Eur Heart J       Date:  2011-01-03       Impact factor: 29.983

4.  Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.

Authors:  Maria Rosa Costanzo; Maya E Guglin; Mitchell T Saltzberg; Mariell L Jessup; Bradley A Bart; John R Teerlink; Brian E Jaski; James C Fang; Erika D Feller; Garrie J Haas; Allen S Anderson; Michael P Schollmeyer; Paul A Sobotka
Journal:  J Am Coll Cardiol       Date:  2007-01-26       Impact factor: 24.094

5.  Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure.

Authors:  Jose E Sánchez; Teresa Ortega; Carmen Rodríguez; Beatriz Díaz-Molina; Maria Martín; Carmen Garcia-Cueto; Pedro Vidau; Emilio Gago; Francisco Ortega
Journal:  Nephrol Dial Transplant       Date:  2009-09-25       Impact factor: 5.992

6.  Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure.

Authors:  Richard Sheppard; Jessica Panyon; Amar L Pohwani; Ajoy Kapoor; Guy Macgowan; Dennis McNamara; Michael Mathier; James R Johnston; Srinivas Murali
Journal:  J Card Fail       Date:  2004-10       Impact factor: 5.712

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.